This webinar roundtable explores interesting technologies, the scientific issues, the clinical opportunities for developing multivalent biologics platforms, whether certain technologies, such as antibodies, their fragments, or non-antibody scaffolds, are superior to others, the pros and cons of such bispecifics for improving management of patients, and licensing and commercial strategies.

并购交易中的意外事件可能会导致交易延迟，甚至完全破坏交易。但如果您知道如何预防这些意外事件，它们是可以避免的。

인수 합병 거래 중 예상하지 못한 일이 벌어진다면 거래의 지연을 야기할 수 있으며 심지어 거래를 완전히 무마시킬 수도 있습니다. 그러나 그러한 상황을 대비하여 불미스러운 일을 피할 수 있습니다.

DELIVER A SLICK, FAST ONBOARDING PROCESS

Get the strategies and insights to create a realistic term sheet that everyone can agree to.

Surprises during M&A transactions can cause delays, even derail deals completely. But they can be avoided if you know.

A vast majority of businesses contract suppliers to provide goods and services to supplement their internal resources.

This all-purpose due diligence checklist contains a list of all the standard documents any buyer or partner might want to see.
.

The Life Sciences due diligence checklist covers unique characteristics applicable to your industry, which buyers or partners may want to examine.

Oncology venture funding, IPOs and partnerships have been exceptionally high in deal volume and values. Cancer continues to be the leading therapeutic area in the number and size of early deals, and the oncology pipeline continues to be a rich source of both follow-on agents as well as first-in-class programs.

In this whitepaper, learn what is artificial intelligence and how is it being applied to drug discovery, and much more.

This whitepaper provides a strategic perspective coupled with actionable tips to help guide you through the essential steps that will help maximize your chance of achieving success in biopharma partnering.